TITLE

Drug Watch

PUB. DATE
February 2004
SOURCE
Formulary;Feb2004, Vol. 39 Issue 2, p124
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents various antidepressant agents in late-stage development and approval by the U.S. Food and Drug Administration as of February 2004. New drugs; Latest indications/combinations/formulations; Information resouces on drug development.
ACCESSION #
12289857

 

Related Articles

  • FDA proposes new rules for investigational drugs. LoBuono, Charlotte // Drug Topics;2/5/2007, Vol. 151 Issue 3, p63 

    The article reports that the U.S. Food and Drug Administration (FDA) has proposed regulatory changes to make investigational drugs easily available to patients with serious illnesses with no other treatment options. The proposition also explains the instances and the costs for which a...

  • A New System for Moving Drugs to Market. Woosley, Raymond L.; Rice, Glenn // Issues in Science & Technology;Winter2005, Vol. 21 Issue 2, p63 

    Discusses the drug development process in the U.S. Problems with the process that were identified by the U.S. Food and Drug Administration such as the imbalance of drug pipeline and national investment in pharmaceutical research and development; Need for the incorporation of drug safety in the...

  • New Quality Concepts in Pharmaceuticals. Aksu, Buket; Yegen, Gizem // Journal of Marmara University Institute of Health Sciences;2014, Vol. 4 Issue 2, p96 

    During the recent years, the pharmaceutical industry, trying to adapt itself to innovations by leaps and bounds, has experienced major developments in production information, quality management systems and risk management, and has developed modern production tools that can assist in ensuring the...

  • Current FDA-Related Drug Information - New Drugs Approved by the FDA; New Dosage Forms and Indications Approved by the FDA; Agents Pending FDA Approval; New Drug/Biologics License Applications Filed by Manufacturer; Supplemental Actions Filed by Manufacturer; Significant Labeling Changes or 'Dear Health Professional' Letters Related to Safety Baker, Danial E. // Hospital Pharmacy;Oct2011, Vol. 46 Issue 10, p801 

    Several tables are presented which provide data on drug-related information in connection with the Food and Drug Administration (FDA) including drug approval, drug dosage and indications approval, and biologics license applications filed by the manufacturer.

  • From Molecule to Medicine Cabinet: A Drug's Long Journey from Development to Approval. Onofrey, Bruce E. // Review of Optometry;Jun2013, Vol. 150 Issue 6, p26 

    The article focuses on the drug approval process of the U.S. Food and Drug Administration. It states that first step is preclinical studies in which the molecule is tested on animals and then an Investigational New Drug Application (IND) is filed to FDA to get approval for starting clinical...

  • Plexxikon's Speedy Zelboraf Work Helped by Diagnostic.  // Bioworld Week;8/22/2011, Vol. 19 Issue 33, p1 

    The article reports on the approval of cancer drug, Zelboraf, from Plexxikon Inc. by the U.S. Food and Drug Administration (FDA) in 2011. It states that in a Phase I extension study conducted in 2009, Zelboraf shows 81% response rate. It indicates that the success of the Phase I study results in...

  • What YOU Need to Know About QbR. Ciurczak, Emil W. // Contract Pharma;Jun2014, Vol. 16 Issue 5, p96 

    The article offers information on the question-based review (QBR) format of the U.S. Food and Drug Administration (FDA) for submitting information necessary in amended new drug applications (ANDAs). Among the information required are the drug substance's manufacturer, characterization, and...

  • Getting it to the streets. Wiegler, Laurie // TCE: The Chemical Engineer;Jun2009, Issue 816, p44 

    The article discusses the impact of the hasty approval of drugs by the U.S. Food and Drug Administration (FDA) on people. According to some critics, there are drug companies that hide negative test results and bribe doctors and scientists on the FDA panel. It mentions unmet medical need as a key...

  • Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation. Rising, Kristin; Bacchetti, Peter; Bero, Lisa // PLoS Medicine;Nov2008, Vol. 5 Issue 11, pe217 

    Lisa Bero and colleagues review the publication status of all efficacy trials carried out in support of new drug approvals from 2001 and 2002, and find that a quarter of trials remain unpublished.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics